SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are seeing intense volatility and high trading volume following a successful Phase 3 trial result for its personalized melanoma vaccine. The community is sharply divided, with bulls pointing to the potential for a massive new revenue stream and a classic short squeeze, while bears argue the stock is fundamentally overextended and likely awaiting a dilutive equity offering.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is surging following a record-breaking fiscal Q2 that saw significant growth in revenue and customer assets, bolstered by the recent elimination of the Pattern Day Trader rule. The community is actively debating potential short-squeeze scenarios and aggressive price targets as traders weigh the company's strong earnings beat against historically volatile post-earnings price action.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is rallying following significant short liquidations and renewed institutional interest, with market participants actively debating the impact of government bond buybacks and recent discussions involving high-profile political figures. The community is sharply divided between those signaling a definitive end to the bear cycle and skeptics warning that this surge may be a temporary relief rally fueled by macroeconomic uncertainty.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as institutional investors aggressively increase their positions despite the stock's recent stagnation, fueling community speculation about a potential strategic buyout or breakthrough oncology deal. Investors remain focused on the company's licensing pivot and pending clinical milestones, debating whether the current management can effectively monetize its proprietary Matrix-M adjuvant technology.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF (XBI) is experiencing significant volatility as investors weigh broader macroeconomic concerns against a series of high-stakes clinical trial readouts and potential M&A activity. Community discussion is heavily polarized, with active debates centered on whether individual biotech assets are being artificially suppressed by algorithmic mechanics or if underlying fundamental risks, such as trial design flaws and clinical failures, justify recent sell-offs.

American Bitcoin Corp. engages in the management of a bitcoin accumulation platform. It offers exposure to bitcoin through an industry-first business model that integrates scaled self-mining operations with disciplined accumulation strategies. The company was founded by Eric Trump and Donald John Trump Jr. on October 3, 2018 and is headquartered in Miami, FL.

American Bitcoin Corp. - Ordinary Shares - Class A

American Bitcoin Corp.

American Bitcoin Corp. is experiencing intense community focus as traders debate the stock's future following a reverse stock split, with bulls pointing to the company's Bitcoin treasury as a long-term value play and bears highlighting persistent dilution concerns and the stock's significant decline since inception. The conversation is currently dominated by conflicting views on whether the company's heavy Bitcoin holdings provide a viable foundation for a potential recovery or if retail investors are being sidelined by management's strategic share consolidations.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals is gaining significant investor attention as positive Phase 3 clinical trial results for its avexitide treatment in post-bariatric hypoglycemia trigger analyst target upgrades and speculation about a potential acquisition. The community is actively debating the impact of the company's subsequent equity offering, weighing concerns about near-term dilution against the stock's strong clinical momentum and long-term valuation potential.

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is currently the subject of intense community debate as investors weigh the potential for a major buyout against concerns about rising competitive pressures in the IgA Nephropathy market. While some stakeholders point to the company's strong institutional backing and positive clinical milestones as evidence of undervaluation, others remain cautious about the long-term impact of new entrants and shifting commercial dynamics in the biotech space.

TOSHI

TOSHI is attracting intense community attention as traders anticipate a major short squeeze and a potential breakout from its prolonged consolidation phase. Supporters are actively calling for accumulation, pinning their optimism on upcoming legislative catalysts and broader market momentum for meme tokens on the Base network.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as investors weigh its unique ability to provide cellular broadband directly to standard smartphones against heavy competition from satellite incumbents. The community is actively discussing the stock's long-term commercial potential, institutional backing, and anticipation for upcoming satellite launch cadences.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
